Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Theca

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: EFFICACY OF DAILY INTRATHECAL BACLOFEN TO TREAT CHILDREN WITH SEVERE SPASTICITY
    Active substance: BACLOFEN
    Study summary document link (including results): baclofen-LIR 647A IT8 Art45 listing 2011.xls
    View full study record
    Document reference: 22064
    Study title: LIORESAL: PLASMA BACLOFEN LEVELS IN CHILDREN RECEIVING CHRONIC INTRATHECAL BACLOFEN INFUSION
    Active substance: BACLOFEN
    Study summary document link (including results):
    View full study record
    Document reference: 22065
    Study title: Lioresal: Plasma baclofen levels in children receiving chronic intrathecal baclofen infusion
    Active substance: BACLOFEN
    Study summary document link (including results):
    View full study record
    Document reference: 22080
    Study title: Stark B et al, Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report, Cancer. 2000 Jan 1;88(1):205-16
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26902
    Study title: Sullivan MP et al. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study. Am J Pediatr Hematol Oncol. 1991 Fall;13(3):288-95. Sullivan MP et al. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study. Am J Pediatr Hematol Oncol. 1991 Fall;13(3):288-95.
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25140
    Study title: Sullivan MP et al. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study. Am J Pediatr Hematol Oncol. 1991 Fall;13(3):288-95. Sullivan MP et al. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study. Am J Pediatr Hematol Oncol. 1991 Fall;13(3):288-95.
    Active substance: CYCLOPHOSPHAMIDE
    Study summary document link (including results):
    View full study record
    Document reference: 25141
    Study title: Treatment of meningitis in children with intrathecal gentamicin. - Newman RL - 1967 (Vth Intern. Of Chemotherapy, Vienna, Vol 1/2: 895) - Publication in Gentamicin Registration Dossier - 1978 -
    Active substance: GENTAMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 28943
    Study title: Caksen H, Odabas D, Atas B. Pediatr Neurol Jul 2002;27(1):75 [Abstract]. Seizures in a boy with subacute sclerosing panencephalitis during high-dose intrathecal interferon-alpha therapyCaksen H, Odabas D, Atas B. Pediatr Neurol Jul 2002;27(1):75 [Abstract]. Seizures in a boy with subacute sclerosing panencephalitis during high-dose intrathecal interferon-alpha therapy
    Active substance: INOSINE
    Study summary document link (including results):
    View full study record
    Document reference: 30080
    Study title: Horiguchi Y, Ohya T. No To Hattatsu. 1995 May;27(3):231-7. Successful treatment of subacute sclerosing panencephalitis with long-term intrathecal large dose of alpha-interferon--a case reportHoriguchi Y, Ohya T. No To Hattatsu. 1995 May;27(3):231-7. Successful treatment of subacute sclerosing panencephalitis with long-term intrathecal large dose of alpha-interferon--a case report
    Active substance: INOSINE
    Study summary document link (including results):
    View full study record
    Document reference: 30120
    Study title: Mehta PD, Kulczycki J, Patrick BA, Sobczyk W, Wisniewski HM. J Neurol Sci. 1992 May;109(1):64-8. Effect of treatment on oligoclonal IgG bands and intrathecal IgG synthesis in sequential cerebrospinal fluid and serum from patients with subacute sclerosing panencephalitis.Mehta PD, Kulczycki J, Patrick BA, Sobczyk W, Wisniewski HM. J Neurol Sci. 1992 May;109(1):64-8. Effect of treatment on oligoclonal IgG bands and intrathecal IgG synthesis in sequential cerebrospinal fluid and serum from patients with subacute sclerosing panencephalitis.
    Active substance: INOSINE
    Study summary document link (including results):
    View full study record
    Document reference: 30147
    Study title: Fernandez-Bouzas-A, Ramirez-Jimenez-H, Vazquez-Zamudio-J, Alonso- Vanegas-M, Mendizabal-Guerra-R. Department of Neuroradiology, Hospital 20 de Noviembre, ISSSTE, Mexico City. Brain calcifications and dementia in children treated with radiotherapy and intrathecal methotrexate. Journal of neurosurgical sciences, {J-Neurosurg-Sci}, Oct-Dec 1992, vol. 36, no. 4, p. 211-4, ISSN: 0390-5616.Fernandez-Bouzas-A, Ramirez-Jimenez-H, Vazquez-Zamudio-J, Alonso- Vanegas-M, Mendizabal-Guerra-R. Department of Neuroradiology, Hospital 20 de Noviembre, ISSSTE, Mexico City. Brain calcifications and dementia in children treated with radiotherapy and intrathecal methotrexate. Journal of neurosurgical sciences, {J-Neurosurg-Sci}, Oct-Dec 1992, vol. 36, no. 4, p...
    Active substance: PROCARBAZINE
    Study summary document link (including results):
    View full study record
    Document reference: 34711
    Study title: Sullivan MP et al. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study. Am J Pediatr Hematol Oncol. 1991 Fall;13(3):288-95. Sullivan MP et al. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study. Am J Pediatr Hematol Oncol. 1991 Fall;13(3):288-95.
    Active substance: MITOXANTRONE
    Study summary document link (including results):
    View full study record
    Document reference: 32251
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 19:57:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA